董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan Schechter | 男 | Director and Chairman of the Board | 52 | 10.00万美元 | 7.64 | 2026-03-20 |
| Jason Adelman | 男 | Director | 56 | 6.80万美元 | 1.00 | 2026-03-20 |
| Deborah Meredith | 女 | Director | 66 | 6.40万美元 | 未持股 | 2026-03-20 |
| Peter Holst | 男 | Director, President and Chief Executive Officer | 57 | 74.85万美元 | 0.05 | 2026-03-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Holst | 男 | Director, President and Chief Executive Officer | 57 | 74.85万美元 | 0.05 | 2026-03-20 |
| David Clark | 男 | Chief Financial Officer | 57 | 46.60万美元 | 0.0082 | 2026-03-20 |
董事简历
中英对照 | 中文 | 英文- Jonathan Schechter
-
Jonathan Schechter目前是Chardan Capital Markets，LLC的投资银行业务主管，在那里他帮助MicroCap公司重组其资产负债表、融资需求和并购机会。Schechter先生自2017年3月30日起担任公司董事。从2005年到2007年，Schechter先生担任一家对冲基金的总法律顾问，该基金专门从事管道交易和结构性产品。从1999年到2005年，Schechter先生在Bryan Cave LLP担任公司合伙人，专门代表投资者和投资银行进行管道交易。他还在公司法的所有方面代表众多上市公司并为其提供建议。Schechter先生于1995年以优异成绩毕业于杜克大学（Duke University），获得政治学学士学位，并毕业于福特汉姆法学院（Fordham Law School），获得法学博士学位，并获得纽约州执业律师执照。
Jonathan Schechter joined Board of Directors in May 2023. Mr. Schechter has served as Chairman of the Board since December 18, 2024. Mr. Schechter is a partner of The Special Equities Group, a division of Dawson James Securities, Inc., a full service investment bank specializing in healthcare, biotechnology, technology, and clean tech sectors, since April 2021. Mr. Schechter is one of the founding partners of The Special Equities Opportunity Fund, a long only fund that makes direct investments in micro cap companies and has served in this capacity since Augt 2019. Mr. Schechter currently serves on the Board of Directors of PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a biotechnology company developing pharmaceutical products. He previoly served as a director of TAO Synergies Inc. (Nasdaq: TAOX) and DropCar, Inc. He has extensive experience analyzing and evaluating the financial statements of public companies. Mr. Schechter earned his A.B. in Public Policy/Political Science from Duke University and his J.D. from Fordham University School of Law. - Jonathan Schechter目前是Chardan Capital Markets，LLC的投资银行业务主管，在那里他帮助MicroCap公司重组其资产负债表、融资需求和并购机会。Schechter先生自2017年3月30日起担任公司董事。从2005年到2007年，Schechter先生担任一家对冲基金的总法律顾问，该基金专门从事管道交易和结构性产品。从1999年到2005年，Schechter先生在Bryan Cave LLP担任公司合伙人，专门代表投资者和投资银行进行管道交易。他还在公司法的所有方面代表众多上市公司并为其提供建议。Schechter先生于1995年以优异成绩毕业于杜克大学（Duke University），获得政治学学士学位，并毕业于福特汉姆法学院（Fordham Law School），获得法学博士学位，并获得纽约州执业律师执照。
- Jonathan Schechter joined Board of Directors in May 2023. Mr. Schechter has served as Chairman of the Board since December 18, 2024. Mr. Schechter is a partner of The Special Equities Group, a division of Dawson James Securities, Inc., a full service investment bank specializing in healthcare, biotechnology, technology, and clean tech sectors, since April 2021. Mr. Schechter is one of the founding partners of The Special Equities Opportunity Fund, a long only fund that makes direct investments in micro cap companies and has served in this capacity since Augt 2019. Mr. Schechter currently serves on the Board of Directors of PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a biotechnology company developing pharmaceutical products. He previoly served as a director of TAO Synergies Inc. (Nasdaq: TAOX) and DropCar, Inc. He has extensive experience analyzing and evaluating the financial statements of public companies. Mr. Schechter earned his A.B. in Public Policy/Political Science from Duke University and his J.D. from Fordham University School of Law.
- Jason Adelman
-
Jason Adelman于2019年7月加入我们的董事会。Adelman先生是Burnham Hill Capital Group，LLC（一家私人持有的金融咨询公司）的创始人和管理成员，并担任Cipher Capital Partners LLC（一家私人投资基金）的管理成员。Adelman先生还担任Trio-TechInternational公司（纽约证券交易所代码:TRT）的董事会成员。在2003年创立Burnham Hill Capital Group，LLC之前，Adelman先生担任H.C.Wainwright and Co.，Inc.的投资银行总经理。Adelman先生以优异成绩毕业于宾夕法尼亚大学（University of Pennsylvania），获得经济学学士学位，并从康奈尔法学院（Cornell Law School）获得法学博士学位。
Jason Adelman was the lead banker in Computer Motion's merger with Intuitive Surgical and was a member of the board of directors of Pharmacyclics prior to its acquisition by Abbvie for over $20 billion. Currently, Mr. Adelman serves as a member of the board of directors of Trio Tech International, a global semiconductor services company, and Oblong, Inc., a leader in next generation collaboration technologies. He served as a member of Greenwave Technology Solutions, Inc.'s board of directors from August 2023 to April 2025. Prior to founding Burnham Hill Capital Group, LLC in 2003, Mr. Adelman served as Managing Director of Investment Banking at H.C. Wainwright and Co., Inc. Mr. Adelman holds a B.A. degree in Economics from the University of Pennsylvania and a J.D. degree from Cornell Law School. - Jason Adelman于2019年7月加入我们的董事会。Adelman先生是Burnham Hill Capital Group，LLC（一家私人持有的金融咨询公司）的创始人和管理成员，并担任Cipher Capital Partners LLC（一家私人投资基金）的管理成员。Adelman先生还担任Trio-TechInternational公司（纽约证券交易所代码:TRT）的董事会成员。在2003年创立Burnham Hill Capital Group，LLC之前，Adelman先生担任H.C.Wainwright and Co.，Inc.的投资银行总经理。Adelman先生以优异成绩毕业于宾夕法尼亚大学（University of Pennsylvania），获得经济学学士学位，并从康奈尔法学院（Cornell Law School）获得法学博士学位。
- Jason Adelman was the lead banker in Computer Motion's merger with Intuitive Surgical and was a member of the board of directors of Pharmacyclics prior to its acquisition by Abbvie for over $20 billion. Currently, Mr. Adelman serves as a member of the board of directors of Trio Tech International, a global semiconductor services company, and Oblong, Inc., a leader in next generation collaboration technologies. He served as a member of Greenwave Technology Solutions, Inc.'s board of directors from August 2023 to April 2025. Prior to founding Burnham Hill Capital Group, LLC in 2003, Mr. Adelman served as Managing Director of Investment Banking at H.C. Wainwright and Co., Inc. Mr. Adelman holds a B.A. degree in Economics from the University of Pennsylvania and a J.D. degree from Cornell Law School.
- Deborah Meredith
-
Deborah Meredith于2021年8月加入我们的董事会。Meredith女士目前担任几家高科技公司的董事会成员，顾问和顾问，这些公司在Proofpoint，Aviatrix，Qventus，Alation和Kinsa Health等私营初创公司的战略角色方面拥有丰富经验。Meredith女士拥有超过30年的经验，与公司创始人一起工作，以组建世界一流的团队，构建软件产品并建立运营成功的路线图。Meredith女士在斯坦福大学获得计算机科学硕士学位，并在密歇根大学获得计算机科学和数学学士学位。
Deborah Meredith currently serves as a board member, advisor, and consultant to several high tech companies, with extensive experience in strategic roles with privately held start up companies such as Proofpoint, Aviatrix, Qvent, Alation, and Kinsa Health. Ms. Meredith has more than three decades of experience working hands on with company founders to assemble world class teams, architect software products and establish a roadmap for operational success. Ms. Meredith earned a master's degree in computer science from Stanford University and an undergraduate degree in both computer science and mathematics from the University of Michigan. - Deborah Meredith于2021年8月加入我们的董事会。Meredith女士目前担任几家高科技公司的董事会成员，顾问和顾问，这些公司在Proofpoint，Aviatrix，Qventus，Alation和Kinsa Health等私营初创公司的战略角色方面拥有丰富经验。Meredith女士拥有超过30年的经验，与公司创始人一起工作，以组建世界一流的团队，构建软件产品并建立运营成功的路线图。Meredith女士在斯坦福大学获得计算机科学硕士学位，并在密歇根大学获得计算机科学和数学学士学位。
- Deborah Meredith currently serves as a board member, advisor, and consultant to several high tech companies, with extensive experience in strategic roles with privately held start up companies such as Proofpoint, Aviatrix, Qvent, Alation, and Kinsa Health. Ms. Meredith has more than three decades of experience working hands on with company founders to assemble world class teams, architect software products and establish a roadmap for operational success. Ms. Meredith earned a master's degree in computer science from Stanford University and an undergraduate degree in both computer science and mathematics from the University of Michigan.
- Peter Holst
-
Peter Holst在2013年1月被任命为总裁兼首席执行官之前，曾于2012年10月1日起担任公司业务发展高级副总裁。Holst先生自2013年1月起担任Oblong, Inc.董事，并于2019年7月至2021年12月15日担任董事会主席。Holst先生在协作行业拥有超过28年的经验。在加入Oblong, Inc.之前，Holst先生曾担任Affinity VideoNet，Inc.的首席执行官，以及Raindance Communications的总裁兼首席运营官。Holst先生拥有Ottawa大学工商管理学位。
Peter Holst served as the Company's Senior Vice President for Biness Development since October 1, 2012. Mr. Holst has served as a director of the Company since January 2013 and as Chairman of the Board from July 2019 to December 15, 2021, and from May 28, 2023 to December 18, 2024. Mr. Holst has more than 28 years of experience in the collaboration indtry. Prior to joining the Company, Mr. Holst served as the Chief Executive Officer of Affinity VideoNet, Inc., and as the President and Chief Operating Officer of Raindance Communications. Mr. Holst holds a degree in Biness Administration from the University of Ottawa. - Peter Holst在2013年1月被任命为总裁兼首席执行官之前，曾于2012年10月1日起担任公司业务发展高级副总裁。Holst先生自2013年1月起担任Oblong, Inc.董事，并于2019年7月至2021年12月15日担任董事会主席。Holst先生在协作行业拥有超过28年的经验。在加入Oblong, Inc.之前，Holst先生曾担任Affinity VideoNet，Inc.的首席执行官，以及Raindance Communications的总裁兼首席运营官。Holst先生拥有Ottawa大学工商管理学位。
- Peter Holst served as the Company's Senior Vice President for Biness Development since October 1, 2012. Mr. Holst has served as a director of the Company since January 2013 and as Chairman of the Board from July 2019 to December 15, 2021, and from May 28, 2023 to December 18, 2024. Mr. Holst has more than 28 years of experience in the collaboration indtry. Prior to joining the Company, Mr. Holst served as the Chief Executive Officer of Affinity VideoNet, Inc., and as the President and Chief Operating Officer of Raindance Communications. Mr. Holst holds a degree in Biness Administration from the University of Ottawa.
高管简历
中英对照 | 中文 | 英文- Peter Holst
Peter Holst在2013年1月被任命为总裁兼首席执行官之前，曾于2012年10月1日起担任公司业务发展高级副总裁。Holst先生自2013年1月起担任Oblong, Inc.董事，并于2019年7月至2021年12月15日担任董事会主席。Holst先生在协作行业拥有超过28年的经验。在加入Oblong, Inc.之前，Holst先生曾担任Affinity VideoNet，Inc.的首席执行官，以及Raindance Communications的总裁兼首席运营官。Holst先生拥有Ottawa大学工商管理学位。
Peter Holst served as the Company's Senior Vice President for Biness Development since October 1, 2012. Mr. Holst has served as a director of the Company since January 2013 and as Chairman of the Board from July 2019 to December 15, 2021, and from May 28, 2023 to December 18, 2024. Mr. Holst has more than 28 years of experience in the collaboration indtry. Prior to joining the Company, Mr. Holst served as the Chief Executive Officer of Affinity VideoNet, Inc., and as the President and Chief Operating Officer of Raindance Communications. Mr. Holst holds a degree in Biness Administration from the University of Ottawa.- Peter Holst在2013年1月被任命为总裁兼首席执行官之前，曾于2012年10月1日起担任公司业务发展高级副总裁。Holst先生自2013年1月起担任Oblong, Inc.董事，并于2019年7月至2021年12月15日担任董事会主席。Holst先生在协作行业拥有超过28年的经验。在加入Oblong, Inc.之前，Holst先生曾担任Affinity VideoNet，Inc.的首席执行官，以及Raindance Communications的总裁兼首席运营官。Holst先生拥有Ottawa大学工商管理学位。
- Peter Holst served as the Company's Senior Vice President for Biness Development since October 1, 2012. Mr. Holst has served as a director of the Company since January 2013 and as Chairman of the Board from July 2019 to December 15, 2021, and from May 28, 2023 to December 18, 2024. Mr. Holst has more than 28 years of experience in the collaboration indtry. Prior to joining the Company, Mr. Holst served as the Chief Executive Officer of Affinity VideoNet, Inc., and as the President and Chief Operating Officer of Raindance Communications. Mr. Holst holds a degree in Biness Administration from the University of Ottawa.
- David Clark
David Clark，2013年3月加入公司，担任首席财务官。Clark先生在金融和会计领域拥有30多年的经验。在加入公司之前，Clark先生曾担任上市生物制药公司阿洛斯治疗的财务副总裁、财务主管和代理首席财务官，以及电子商务管理服务公司Seurat Company（前身为XOR，Inc.）的首席财务官。Clark先生开始了他的职业生涯，在普华永道会计师事务所的审计工作中度过了七年。Clark先生是一名现役注册会计师，并在丹佛大学获得了会计学硕士学位和会计学学士学位。
David Clark,joined the Company in March 2013 as Chief Financial Officer ("CFO"). Mr. Clark has more than 30 years of experience in finance and accounting. Prior to joining the Company, Mr. Clark served as Vice President of Finance, Treasurer, and acting CFO for Allos Therapeutics, a publicly traded biopharmaceutical company, and as CFO of Seurat Company (formerly XOR, Inc.), an e-commerce managed services company. Mr. Clark began his career with seven years in the audit practice of PricewaterhouseCoopers LLP. Mr. Clark is an active Certified Public Accountant and received a Master of Accountancy and a B.S. in Accounting from the University of Denver.- David Clark，2013年3月加入公司，担任首席财务官。Clark先生在金融和会计领域拥有30多年的经验。在加入公司之前，Clark先生曾担任上市生物制药公司阿洛斯治疗的财务副总裁、财务主管和代理首席财务官，以及电子商务管理服务公司Seurat Company（前身为XOR，Inc.）的首席财务官。Clark先生开始了他的职业生涯，在普华永道会计师事务所的审计工作中度过了七年。Clark先生是一名现役注册会计师，并在丹佛大学获得了会计学硕士学位和会计学学士学位。
- David Clark,joined the Company in March 2013 as Chief Financial Officer ("CFO"). Mr. Clark has more than 30 years of experience in finance and accounting. Prior to joining the Company, Mr. Clark served as Vice President of Finance, Treasurer, and acting CFO for Allos Therapeutics, a publicly traded biopharmaceutical company, and as CFO of Seurat Company (formerly XOR, Inc.), an e-commerce managed services company. Mr. Clark began his career with seven years in the audit practice of PricewaterhouseCoopers LLP. Mr. Clark is an active Certified Public Accountant and received a Master of Accountancy and a B.S. in Accounting from the University of Denver.